[
  {
    "ts": null,
    "headline": "Boston Scientific Corp. stock outperforms competitors despite losses on the day",
    "summary": "Boston Scientific Corp. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=4c5b473a899d8168f9fcf162604d00301ddb7f8bf4002375e5e395dcc0fb7d00",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732034400,
      "headline": "Boston Scientific Corp. stock outperforms competitors despite losses on the day",
      "id": 131508797,
      "image": "",
      "related": "BSX",
      "source": "MarketWatch",
      "summary": "Boston Scientific Corp. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=4c5b473a899d8168f9fcf162604d00301ddb7f8bf4002375e5e395dcc0fb7d00"
    }
  },
  {
    "ts": null,
    "headline": "Reasons to Retain BSX Stock in Your Portfolio for Now",
    "summary": "Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.",
    "url": "https://finnhub.io/api/news?id=f1b3cc88b9b05d10f31500570c3ca9dbe6d1d433aecd9946a128a293c76ee5b7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732022580,
      "headline": "Reasons to Retain BSX Stock in Your Portfolio for Now",
      "id": 131471556,
      "image": "https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Investors remain optimistic about Boston Scientific due to its geographical expansions and impressive acquisitions.",
      "url": "https://finnhub.io/api/news?id=f1b3cc88b9b05d10f31500570c3ca9dbe6d1d433aecd9946a128a293c76ee5b7"
    }
  },
  {
    "ts": null,
    "headline": "BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX",
    "summary": "Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.",
    "url": "https://finnhub.io/api/news?id=8f4b9a54955586f25f8383961002a391e387819cb45ffde9afd4a3898f399062",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732022520,
      "headline": "BSX Stock Gains From Positive OPTION Trial Data for WATCHMAN FLX",
      "id": 131471557,
      "image": "https://media.zenfs.com/en/zacks.com/ae98f9f4477af1de31a0a61cde692d41",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "Boston Scientific announces favorable OPTION trial results for its WATCHMAN FLX LAAC device. In terms of stroke risk reduction, WATCHMAN FLX is found to be superior to OAC therapy.",
      "url": "https://finnhub.io/api/news?id=8f4b9a54955586f25f8383961002a391e387819cb45ffde9afd4a3898f399062"
    }
  },
  {
    "ts": null,
    "headline": "Boston Scientific Stock Set to Gain From Completion of Axonics Deal",
    "summary": "BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.",
    "url": "https://finnhub.io/api/news?id=abef8fbc8648546dcf33142f1ccb1837d5857a18e59fdf5e1178a73ddabbc187",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732020600,
      "headline": "Boston Scientific Stock Set to Gain From Completion of Axonics Deal",
      "id": 131471558,
      "image": "https://media.zenfs.com/en/zacks.com/c8704ffaba0234da981fa842a48f77b5",
      "related": "BSX",
      "source": "Yahoo",
      "summary": "BSX's acquisition of Axonics marks its entry into sacral neuromodulation and complements its Urology business.",
      "url": "https://finnhub.io/api/news?id=abef8fbc8648546dcf33142f1ccb1837d5857a18e59fdf5e1178a73ddabbc187"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Balanced Fund Q3 2024 Review",
    "summary": "Fidelity Balanced Fund invests across a mix of stocks and bonds â with a 60%/40% neutral allocation â in seeking income and capital growth.",
    "url": "https://finnhub.io/api/news?id=41a9a58b6b0d73030ef478b1963404273a25a82ffe73fe5b99907a2efd45d407",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731998400,
      "headline": "Fidelity Balanced Fund Q3 2024 Review",
      "id": 131468619,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310052459/image_1310052459.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "Fidelity Balanced Fund invests across a mix of stocks and bonds â with a 60%/40% neutral allocation â in seeking income and capital growth.",
      "url": "https://finnhub.io/api/news?id=41a9a58b6b0d73030ef478b1963404273a25a82ffe73fe5b99907a2efd45d407"
    }
  },
  {
    "ts": null,
    "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
    "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731993000,
      "headline": "Fidelity Select Health Care Portfolio Q3 2024 Fund Review",
      "id": 131467028,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1849023174/image_1849023174.jpg?io=getty-c-w1536",
      "related": "BSX",
      "source": "SeekingAlpha",
      "summary": "For Q3 2024, the Fidelity Select Health Care Portfolio fund gained 9.48%, outperforming the MSCI sector index. Click here to read the full commentary.",
      "url": "https://finnhub.io/api/news?id=f19c540ed18a1c2f912d6ff2c1c5be2a7f351bca6a9d716c8a57b31d84916382"
    }
  }
]